NEWS
MucoLife Turns a Vinnova Grant Into a COPD Factory Recipe
Vinnova awarded MucoLife Therapeutics SEK 1 million to write a transferable purification process for MLT-001, an inhaled COPD peptide, ahead of planned 2027 trials.
MucoLife Therapeutics received SEK 1 million from Vinnova to scale purification of MLT-001, its inhaled peptide for COPD mucus plugs.
The 6 November 2026 award is the ceiling of a Swedish call that pays small firms to use domestic life-science plant and lab services, and it lands while the Gothenburg company still aims to open Phase I trials in 2027.
The Million Kronor Goes to a Swedish Factory Floor
The money comes through the call “Support to small and medium-sized companies for the use of life science infrastructure.” Vinnova, Sweden’s innovation agency, designed that round to buy time on Swedish research kit and technology plants, not to fund a full drug programme. Projects can be granted up to one million SEK over 18 months, which is exactly what MucoLife booked.
Eligible costs in the call are consultancy from the plant or lab that does the work. Vinnova will not pay basic research, work the company could do itself, or a file that is mainly business or regulatory. It will pay for process scale-up and for adapting methods toward Good Manufacturing Practice. In plain terms, the grant is a factory invoice.
MucoLife said synthesis of MLT-001 is already scalable. The new work, done with an unnamed contract development and manufacturing organisation, is supposed to reach a usable purity at a documented yield, then hand over a transferable process description and a control strategy that a later GMP shop can copy. Thaher Pelaseyed, PhD, co-founder and chief executive, put the bottleneck in one line.
Manufacturing is the step that turns a promising molecule into a medicine. With Vinnova’s support, we can build the purification process for MLT-001 and move closer to clinical trials.
Thaher Pelaseyed, CEO, MucoLife Therapeutics
Applicants had to show contact with the Swedish plant by the 9 September 2026 close, and attach a statement of intent. The partner’s name is still private, but the form would not have cleared without a Swedish site already on the paper. GU Ventures, the University of Gothenburg holding company that has backed the spinout from the start, posted the award in Swedish on the morning of 6 November 2026.
Stort grattis till MucoLife Therapeutics, ett av GU Ventures bolag, som har beviljats 1 miljon kronor från Vinnova för att vidareutveckla läkemedelskandidaten MLT-001 mot KOL! 🫁#GUVentures #Vinnova #LifeScience #Innovation #KOL #GöteborgsUniversitethttps://t.co/Om2fODb3YS
— GU Ventures (@GUVentures) November 6, 2026
Converted, SEK 1 million is €91,000. That is a rounding error beside a first-in-human budget, which is why the call is written around plant invoices rather than salaries. The project must start between 1 and 11 November 2026 and finish no later than 30 May 2028.
THE VINNOVA INFRASTRUCTURE CALL
- The ceiling: A project can receive SEK 1 million over 18 months, and MucoLife took the full amount.
- The bill: Vinnova funds the infrastructure’s consultancy, including process scale-up and GMP-facing method work.
- The window: Bids closed at 14:00 on 9 September 2026; work starts 1 to 11 November 2026 and must end by 30 May 2028.
- The gate: The company had to attach a statement of intent from a Swedish plant before it applied.
Nordic funding notes filed the cheque beside far larger rounds in the same week. That filing misses the design of the call. Sweden is buying a recipe a GMP plant can run, because an academic peptide that cannot be purified at scale never becomes a medicine.
Mucus Plugs Show Up on Scans and Raise the Death Rate
MLT-001 is aimed at a feature of COPD that inhalers already on the market do not treat as a target. Mucus plugging, visible on chest CT as blocked medium and large airways, tracks with worse lung function, more flare-ups, and higher death rates, even in people who do not cough much. MucoLife says plugging is present in more than half of patients with moderate-to-severe disease, and that no approved drug hits the plugs directly.
Large cohorts put the share in a wide band. Emily Wan, MD, MPH, of VA Boston, Brigham and Women’s Hospital, and Harvard Medical School, told the 2026 GOLD International COPD Conference that prevalence ran from 31% in RealDTC to 67% in SPIROMICS, with COPDGene in between. About one-third of plugs in those data were silent, meaning no cough or phlegm, and Wan said those silent plugs still lined up with poorer exercise tolerance, faster loss of lung function, and more prior exacerbations.
The Genetic Epidemiology of COPD study, COPDGene, is the set with the cleanest death counts. Among 4,363 patients followed for a median 9.5 years, 40.7% had plugs in at least one segment. All-cause deaths rose with the number of blocked segments, and the link held after adjustment for age, smoking, FEV1, emphysema, and airway wall thickness. Alejandro A. Diaz, MD, MPH, of Brigham and Women’s, said therapies that break up the plugs could improve outcomes, which is the bet MucoLife is trying to industrialise.
DEATH RATES IN THE COPDGENE COHORT
| Mucus plug burden | Patients | Share of 4,363 | Deaths over 9.5 years |
|---|---|---|---|
| None | 2,585 | 59.3% | 34.0% |
| 1 to 2 lung segments | 953 | 21.8% | 46.7% |
| 3 or more segments | 825 | 18.9% | 54.1% |
Relative to patients with no plugs, the adjusted hazard of death was 1.15 with plugs in 1 to 2 segments and 1.24 with plugs in 3 or more. A later seven-study analysis of 15,702 patients found a 14% higher all-cause death risk (hazard ratio 1.14) for low-grade plugs scored 1 to 2. COPD affects 15.9 million people in the United States and ranks as the fourth leading cause of death there, which is why a small purification grant is being asked to carry more weight than its size suggests.
How MLT-001 Loosens Calcium-Locked Mucus
The molecule is a mucus modulator, not a steroid and not a bronchodilator. Pelaseyed, an associate professor at the Institute of Biomedicine, University of Gothenburg, has spent more than 20 years on mucin biology. He said the company set out to learn, at a molecular level, how the plugs that clog patients’ lungs are formed and held together, then to interfere with those mucin-to-mucin contacts without shutting mucus off entirely, because even a COPD lung still needs a working mucus defence against infection.
The chemistry sits in a granted US patent on calcium-binding gamma-carboxy glutamate peptides, US 10,035,821 B2, with Gunnar C. Hansson, Anna Ermund, and Christian Recktenwald as inventors. Mucins pack in secretory granules at low pH with calcium; if that calcium is not stripped on release, the gel stays stuck to the airway. The patent says a peptide with eight gamma-carboxy glutamic acid units can bind calcium at low nanomolar concentrations, compete it off mucin, and get attached cystic fibrosis mucus moving again in pig trachea. Hansson, MD, PhD, is MucoLife’s co-founder and chief scientific officer.
University of Gothenburg reported that studies in mice and pigs showed mucus plugs reduced by up to 90 percent. At the European Respiratory Society Congress in Barcelona, 5 to 9 September 2026, Hansson’s poster was titled “A γ-carboxyglutamate polymer detaches airway mucus and restores functional airway patency in a murine model of muco-obstructive lung disease.” He also gave an invited talk, “Too Much, Too Thick, Too Sticky.” That is still animal work. No patient has inhaled a GMP batch.
Once inhaled, MLT-001 will directly reach the mucus plugs. It will not affect the cells in your lungs or cross over into your blood. Another challenge when designing an inhaled medicine is that most patients also swallow some of the drug they’ve inhaled. Which means that if you have a drug that is affecting or dissolving mucus in your lungs, you don’t want to have that effect in the gut. Because the mucus has a very important protective function against the gut bacteria. And that is also our differentiator. Our drug does not cause any gastrointestinal side effects because it is readily degraded when it reaches the stomach and the upper parts of the intestines.
Thaher Pelaseyed, CEO, MucoLife Therapeutics, at GoWest
The target product, he said, is one dose a day in a standard inhaler, worked backwards from talks with patients and pulmonologists. Delivery is a separate track. In May 2026 the company won support from Medtech4Health and Vinnova, under “Kompetensförstärkning i småföretag 2026,” to plan a dual-use nebulizer for hospitals, intensive care, home care, and crisis settings. That award funds a roadmap and outside expertise, not a device on a shelf.
Forty Years of Gothenburg Mucin Work
MucoLife launched on 11 June 2024 from the Mucin Biology Groups at Gothenburg, which the company credits with 40 years of mucin research at Sahlgrenska Academy. Pelaseyed and Hansson founded it with GU Ventures involved from the start. The public roster now also lists Kicki Johansson, PhD, as chief development officer, Maarten Kraan, MD, PhD, as chief clinical officer (he joined the board on 11 April 2025), Jim Shaffer as chief business officer, and consultants on drug product and preclinical safety, among them Gary Pitcairn, PhD. Anders Waas chairs the board.
In September 2024 the company was one of ten startups chosen by Dallas accelerator Health Wildcatters from nearly 700 applications, a US door the founders wanted for investor meetings. Pelaseyed later presented at Science2Startup in Boston in May 2025, at BioNTX in Texas, and with Business Sweden’s Team Sweden at JP Morgan Healthcare Week in San Francisco, 12 to 15 January 2026. Klementina Österberg, chief executive of GU Ventures, has repeatedly used the company as proof that Gothenburg mucin work can travel.
Public money has been small and specific. A Vinnova planning grant of SEK 300,000 ran from April to December 2025 under a global-cooperation call, reference 2025-00617, to prepare an EIC Transition bid. The company wrote that the work produced a business model, a market plan, and a path through Phase I, but it did not win EIC Transition funds. The new million kronor does not replace that missed cheque. It pays a different bill.
FROM LAUNCH TO THE FACTORY GRANT
- 11 June 2024: MucoLife Therapeutics launches in Gothenburg around MLT-001.
- September 2024: Health Wildcatters picks the company as one of ten from nearly 700 applications.
- April to December 2025: A SEK 300,000 Vinnova planning grant runs; the EIC Transition bid fails.
- May 2025: Pelaseyed presents at Science2Startup in Boston; the university reports the mouse and pig plug cuts.
- May 2026: Medtech4Health and Vinnova fund planning for a dual-use nebulizer.
- 5 to 9 September 2026: Hansson presents the murine patency data at ERS in Barcelona.
- 6 November 2026: Vinnova awards SEK 1 million for scaled purification with a contract manufacturer.
Hansson has said the spinout shows what basic work at Sahlgrenska can become. The next test is whether a purification method written on an 18-month voucher can be copied in a GMP suite in time for 2027.
The 2027 Trial Clock Still Needs That Recipe
Pelaseyed has said Phase I should open by 2027, first for safety, with a chance to collect efficacy in a tight patient subset. The University of Gothenburg used the same year in May 2025, when it said the company was still raising the money to start those studies. At Nordic Life Science Days in Gothenburg in September 2026, Pelaseyed pitched in Business Region Göteborg’s stand while that raise was still open. None of those dates is a regulator’s clock. They are a company’s target, and they assume a clean, documented peptide coming off a plant that does not yet have the process in a transferable file.
That is the list this grant is supposed to finish. If the contract manufacturer delivers, MucoLife walks into a financing meeting with more than a mouse poster. If it does not, 2027 slips for a reason that has nothing to do with mucin biology.
WHAT THE CDMO FILE MUST CONTAIN
- Purity: A scaled process that reaches a purity the company can defend in a later GMP suite.
- Yield: The same process with a documented yield, so a batch size is not a guess.
- Transfer pack: A written process description another plant can pick up without the inventors in the room.
- Control strategy: The checks that would sit behind later GMP manufacture of MLT-001.
The company has already said the peptide can be made. Purification is the harder industrial step for a charged calcium-binding polymer that has to be inhaled, and it is the step Vinnova is willing to put on a Swedish plant’s invoice. GMP batches, toxicology, and the trial itself sit outside that invoice.
N-Acetylcysteine Has Gone Unchallenged Since 1963
The marketed comparison Pelaseyed uses is blunt. N-acetylcysteine, a mucolytic approved in 1963, still stands in as the mucus-dissolving drug physicians can name. He said it permanently breaks strong bonds in mucin proteins and shatters the gel into fragments so small the lung cannot clear them well. In a February 2025 conversation at GoWest he put the company’s animal clearance against that bar, and he argued there had been almost no product progress in the six decades after the 1963 approval.
Current treatment options fail to address mucus plugs, leaving a critical gap in COPD patient care. Unfortunately, there are no standard treatments today that really help these patients. There is a critical unmet need.
Thaher Pelaseyed, CEO, MucoLife Therapeutics, at GoWest
He also said the company’s treatment showed 90 per cent efficacy in mucus clearance against 5 per cent for N-acetylcysteine. That pair is his comparison, on the same animal work the university described as plug cuts of up to 90 percent in mice and pigs. It is not a head-to-head trial in people. Classic mucoactive pills have a thin record against CT-visible plugs in COPD, which is why GOLD 2026 spent time on imaging scores rather than on another expectorant.
Pelaseyed’s longer plan is to carry mucus-modulating leads through early clinical work, then license them to large respiratory companies. He noted that the top five drug makers all keep respiratory portfolios, and that a lot of early academic bets die because the target or the lead is wrong. MucoLife’s pitch is that the target is now visible on CT and the lead is a peptide whose synthesis already scales. The missing piece, until this grant, was a purification file a plant would accept.
What the Grant Leaves Unpaid
SEK 1 million will not dose a patient. The call forbids using it for the business plan, the regulatory file, or work the staff could do in their own lab. It will not buy the 2027 trial, the remaining toxicology, or a commercial inhaler. The May 2026 nebulizer project is only a planning exercise. The failed EIC Transition bid already showed that a polished plan is not the same as European cash.
WHAT WE KNOW
- The award: SEK 1 million (€91,000) from Vinnova on 6 November 2026, the call’s ceiling, for scaled purification of MLT-001.
- The biology: An inhaled gamma-carboxyglutamate polymer meant to unstick calcium-locked mucin; animal plug cuts up to 90 percent; no human GMP dose yet.
- The clock: Process work must start by 11 November 2026 and end by 30 May 2028; the company still cites 2027 for Phase I.
WHAT IS UNCONFIRMED
- The plant: The contract manufacturer is unnamed, though a Swedish statement of intent had to be on the bid.
- The raise: Size, lead investor, and close date for the trial round have not been disclosed.
- The clinic: Phase I country, site, and whether COPD or cystic fibrosis goes first remain open.
By 30 May 2028, Vinnova will either have a transferable purification pack for MLT-001 or a closed file that never left the plant. The 2027 first-in-human date only holds if that pack exists, and if someone else pays for everything the million kronor was never allowed to buy.
Disclaimer: This article is news reporting on a public grant and a preclinical drug candidate, and it is for information only. It is not medical advice, a treatment recommendation, or investment advice, and it does not assess whether MLT-001 is safe or effective in people. Readers who have COPD or another lung disease should talk with a qualified physician before changing care, and anyone weighing a financial interest in a private biotech should consult a licensed financial adviser. Figures, trial dates, and partner details reflect the company, Vinnova, and university statements available on 6 November 2026 and may change as the manufacturing project and any financing round move.
-
BUSINESS5 months agoAramco Crash Kills 14 Two Days After Oil Restart
-
NEWS6 months agoSalah Captained Egypt to Their First World Cup Win
-
GAMING2 months agoZelda’s 40th Switch 2 Ships Without a Zelda Game
-
NEWS3 months agoApple Labor Day Deals Hide June’s Memory Price Hike
-
NEWS4 months agoEl Niño Puts Israel’s Needed Winter Rain on a Flood Clock
-
GAMING2 months agoPalworld 1.0.4 Adds Palpedia Search After the 1.0 Launch
-
NEWS4 months agoSaudi Visa Routes Split Nigerian Travelers Into Two Speeds
-
BUSINESS9 months agoBAE’s 60-Year Saudi Franchise Now Runs Through Taif
